SB 202474 (CAS 172747-50-1)

SB 202474, known chemically as 4-[4-ethyl-2-(4-methoxyphenyl)-1H-imidazol-5-yl]-pyridine, is intricately designed to serve as a pivotal negative control within the realm of biochemical research, particularly in experiments investigating the inhibition of p38 MAP kinase through the use of SB202190 and SB203580. This compound is a structural analog of SB 202190 and SB 203580, which are distinguished by their potent and selective inhibition capabilities targeting p38α and p38β MAP kinase isoforms. The significance of SB 202474 lies in its molecular design, which closely mirrors that of its counterparts, albeit without exhibiting inhibitory activity against the p38 MAP kinase enzymes. This characteristic makes it an invaluable tool for discerning the specific biochemical pathways and molecular interactions modulated by the active inhibitors. By providing a chemically similar yet functionally distinct comparison, SB 202474 facilitates the rigorous assessment of the efficacy and specificity of p38 MAP kinase inhibition, thereby enriching our understanding of kinase signaling pathways and their modulation. Its role in research extends beyond mere negative control; it aids in elucidating the nuanced mechanisms of action of kinase inhibitors, ensuring that observed biological effects are directly attributable to the intended enzymatic target inhibition, thereby advancing the field of biochemical and cellular research.